Transgender women are still at risk for prostate cancer. A new study led by Cedars-Sinai Cancer investigators, published in JAMA concludes that current screening guidelines could miss early-stage prostate cancer in transgender women on hormone therapy. The prostate, a small gland that helps make semen, also produces a protein called prostate-specific antigen, or PSA. Blood levels of PSA tend to be elevated in people who have prostate cancer, and the PSA test, which measures those levels, is a common prostate cancer screening tool. “Many transgender women take estrogen as part Read More